Alterity Therapeutics is a late clinical-stage biotech company focused on developing treatments for serious neurodegenerative ...

US FDA grants fast track designation to Complement Therapeutics’ gene therapy candidate CTx001 to treat geographic atrophy: Munich Saturday, January 10, 2026, 17:00 Hrs [IST] Co ...

January 07, 2026-- NeuraLight, the leader in developing precision biomarkers for neurology, today announced the completion of PALOMA, a pioneering study comparing eye-movement measures with standard ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.

Longtime Texas high school football coach Mike Robinson has died, DeSoto coach Claude Mathis confirmed to The Dallas Morning ...

Multiple sclerosis (MS) is a disorder that prompts the body's immune system to attack myelin, the protective sheath covering nerve cells in the brain, optic nerve and spinal cord. This can in turn ...

In a clinical trial spanning two years, lipoic acid was shown to slow brain atrophy in people with progressive multiple sclerosis. However, the antioxidant failed to ease symptoms such as fatigue.

MELBOURNE, Australia and SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...